Recurrent Uterine Corpus Carcinoma
33
0
2
28
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Published Results
17 trials with published results (52%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 33 trials
100.0%
+13.5% vs benchmark
3%
1 trials in Phase 3/4
61%
17 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 28 completed trials
Clinical Trials (33)
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Biomarkers in Samples From Patients With Endometrial Cancer
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer